Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Maravai Lifesciences Holdings (MRVI) over the last 4 years, with Q3 2025 value amounting to $243.6 million.

  • Maravai Lifesciences Holdings' Cash & Equivalents fell 5787.06% to $243.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.6 million, marking a year-over-year decrease of 5787.06%. This contributed to the annual value of $322.4 million for FY2024, which is 4392.69% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Cash & Equivalents stood at $243.6 million for Q3 2025, which was down 5787.06% from $269.9 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year Cash & Equivalents high stood at $632.1 million for Q4 2022, and its period low was $243.6 million during Q3 2025.
  • For the 4-year period, Maravai Lifesciences Holdings' Cash & Equivalents averaged around $472.8 million, with its median value being $573.2 million (2024).
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Cash & Equivalents dropped by 24.98% in 2024, and later tumbled by 5787.06% in 2025.
  • Maravai Lifesciences Holdings' Cash & Equivalents (Quarter) stood at $632.1 million in 2022, then dropped by 9.04% to $575.0 million in 2023, then tumbled by 43.93% to $322.4 million in 2024, then fell by 24.45% to $243.6 million in 2025.
  • Its Cash & Equivalents was $243.6 million in Q3 2025, compared to $269.9 million in Q2 2025 and $285.1 million in Q1 2025.